Evidence map›Paper›PMID 38427741›Full record

ArticleScience advances2024

Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions.

Adam R Wolfe, Tiantian Cui, Sooin Baie, Sergio Corrales-Guerrero, Amy Webb, Veronica Castro-Aceituno, Duan-Liang Shyu, Joanna M Karasinska, James T Topham, Daniel J Renouf and 10 more

Open access · goldAbstract read
In one paragraph

Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 4 countries.

Adam R WolfeDepartment of Radiation Oncology, The University of Arkansas for Medical Sciences, The Winthrop P. Rockefeller Cancer Institute, Little Rock, AR, USA.ORCID 0000-0002-0123-7371
Tiantian CuiDepartment of Radiation Oncology, City of Hope, Duarte, CA, USA.
Sooin BaieDepartment of Cancer Biology and Genetics, The Ohio State University Wexner Medical Center, Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, Columbus, OH, USA.ORCID 0009-0000-8534-4184
Sergio Corrales-GuerreroDepartment of Radiation Oncology, City of Hope, Duarte, CA, USA.ORCID 0000-0002-5107-3475
Amy WebbDepartment of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.
Veronica Castro-AceitunoDepartment of Radiation Oncology, City of Hope, Duarte, CA, USA.ORCID 0000-0002-5285-3975
Duan-Liang ShyuDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, Columbus, OH, USA.
Joanna M KarasinskaPancreas Centre BC, Vancouver, BC, Canada.ORCID 0000-0001-6861-4189
James T TophamPancreas Centre BC, Vancouver, BC, Canada.
Daniel J RenoufPancreas Centre BC, Vancouver, BC, Canada.
David F SchaefferPancreas Centre BC, Vancouver, BC, Canada.
Megan HalloranDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, Columbus, OH, USA.
Rebecca PackardDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, Columbus, OH, USA.
Ryan RobbDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-7661-7902
Wei ChenDepartment of Pathology, The Ohio State University Wexner Medical Center, Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, Columbus, OH, USA.ORCID 0000-0002-9028-622X
Nicholas DenkoDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, Columbus, OH, USA.
Michael LisantiTranslational Medicine, University of Salford, Greater Manchester M5 4WT, UK.
Timothy C ThompsonDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, USA.ORCID 0000-0003-1424-3831
Philippe FrankSGS France, Health & Nutrition, Saint-Benoît, France.ORCID 0000-0003-4857-5279
Terence M WilliamsDepartment of Radiation Oncology, City of Hope, Duarte, CA, USA.ORCID 0000-0002-1020-0845
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USCity of Hope · USPancreas Centre (Canada) · CAiProgen Biotech (Canada) · CAThe Ohio State University · USThe University of Texas MD Anderson Cancer Center · USUniversité de Tours · FRUniversity of North Carolina at Chapel Hill · USVancouver General Hospital · CAWinthrop Rockefeller Foundation · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
Institutional Career DevelopmentKL2TR003108 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI ARTHUR, JOHN M., BORSHEIM, ELISABET · 2019 to 2023
$2.3M
Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid CancerR01CA246553 · NCI · OHIO STATE UNIVERSITY · PI WILLIAMS, TERENCE MARQUES · 2020 to 2025
$2.0M
NCATS NIH HHS KL2 TR003108NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA246553
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is characterized by its nutrient-scavenging ability, crucial for tumor progression. Here, we investigated the roles of caveolae-mediated endocytosis (CME) in PDAC progression. Analysis of patient data across diverse datasets revealed a strong association of high caveolin-1 (Cav-1) expression with higher histologic grade, the most aggressive PDAC molecular subtypes, and worse clinical outcomes. Cav-1 loss markedly promoted longer overall and tumor-free survival in a genetically engineered mouse model. Cav-1-deficient tumor cell lines exhibited significantly reduced proliferation, particularly under low nutrient conditions. Supplementing cells with albumin rescued the growth of Cav-1-proficient PDAC cells, but not in Cav-1-deficient PDAC cells under low glutamine conditions. In addition, Cav-1 depletion led to significant metabolic defects, including decreased glycolytic and mitochondrial metabolism, and downstream protein translation signaling pathways. These findings highlight the crucial role of Cav-1 and CME in fueling pancreatic tumorigenesis, sustaining tumor growth, and promoting survival through nutrient scavenging.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAnimalsCaveolaeCell Line, TumorEndocytosisHumansMiceSignal Transduction

Identifiers

PMID38427741
PMCPMC10906919
OpenAlexW4392388751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.